


Slovenia

Factor VIII per capita compared to other countries

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline

		2009	2012	2015	2018
International units per capita	Factor VIII	0.00	▲ 5.91	▲ 8.02	▲ 8.43
	Factor IX	0.00	▲ 0.45	▼ 0.44	▲ 0.56
Organisation of care	Comprehensive Care Centres (CCC's)	Yes	Yes	Yes	Yes
	Haemophilia Treatment Centres	No	No	No	No
	National Haemophilia Council or Co-ordinating Group		Yes	Yes	▼ No
	Number of groups in decision-making on haemophilia care	0	▲ 2	▲ 3	▼ 2
	Number of groups choosing haemophilia treatment products	0	▲ 2	2	2
	National Tender for procurement of factor concentrates		No	▲ Yes	Yes
Treatment regimens	Home Treatment	Yes	Yes	Yes	Yes
	% of people with haemophilia using home treatment	10-50%	10-50%	▲ 76-100%	▼ 51-75%
	Treatment delivered to the patient's home	Some	Some	No	No
	Prophylaxis treatment availability	Yes	Yes	Yes	Yes
	Children currently on prophylaxis (%)	26-50%	26-50%	▲ 76-100%	76-100%
	Adults currently on prophylaxis (%)	26-50%	26-50%	▲ 76-100%	▼ 51-75%
	Access to ITI (% of people with inhibitors)	76-99%	76-99%	▲ 100%	100%
Access to specialist services	Emergency medicine and acute surgery		Yes	Yes	Yes
	Paediatrics		Yes	Yes	Yes
	Infectious disease specialists (especially HIV)		Yes	Yes	Yes
	Hepatology		Yes	Yes	Yes
	Rheumatology		Yes	Yes	▼ Never
	Orthopaedics		Yes	Yes	Yes
	Physiotherapy		Yes	Yes	Yes
	Dentistry		Yes	Yes	Yes
	Obstetrics and Gynaecology		Yes	Yes	Yes
	Genetics		Sometimes	▲ Yes	Yes
	Social and psychological support		Sometimes	▲ Yes	▼ Never
	Pain management		Yes	▼ Sometimes	▼ Never
	General surgery		Yes	Yes	Yes
	Urology		Yes	Yes	Yes
Share of Expected Bleeding Disorder Prevalence	Haemophilia A		88%	▲ 93%	▲ 103%
	Haemophilia B		34%	▲ 37%	▲ 48%
	von Willebrand Disease		7%	▲ 9%	▲ 9%
Haemophilia replacement therapy	Plasma-derived factor concentrate	Always	Always	▼ Rarely	Rarely
	Recombinant factor concentrate		Always	Always	Always
	Plasma	Never	▼ Rarely	▲ Never	Never
	Cryoprecipitate	Never	Never	Never	Never
VWD replacement therapy	Plasma-derived factor concentrate		Always	Always	Always
	DDAVP		Rarely	▲ Always	▼ Rarely
	Plasma		Rarely	▲ Never	Never
	Cryoprecipitate		Never	Never	Never